InMode initiated with an Overweight at Barclays

Barclays analyst Matt Miksic initiated coverage of InMode with an Overweight rating and $44 price target. The company’s "differentiated" minimally invasive BodyTite and Morpheus8 platforms have created an array of aesthetic treatments which are less invasive than surgical procedures like liposuction, but more effective than non-invasive treatments like laser therapy, Miksic tells investors in a research note. The analyst believes IInMode is well positioned to continue to lead growth over the next 12-24 months within its current clinical customer base.